Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CBX7 | O95931 | 1/20 | 0.34 |
| ▸ | CDYL2 | Q8N8U2 | 1/20 | 0.34 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.34 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16696106 | 0.80 | GAA (0.48) | SMN1; SMN2GAA | |
| SCHEMBL20096956 | 0.75 | GAA (0.36) | SMN1; SMN2GAA | |
| SCHEMBL21311367 | 0.74 | SMN1; SMN2 (0.38) | SMN1; SMN2GAA | |
| SCHEMBL13157560 | 0.70 | SMN1; SMN2 (0.39) | SMN1; SMN2GAA | |
| SCHEMBL17297883 | 0.66 | SMN1; SMN2 (0.39) | SMN1; SMN2GAA | |
| SCHEMBL15131073 | 0.66 | SMN1; SMN2 (0.39) | SMN1; SMN2GAA | |
| SCHEMBL8083341 | 0.65 | OPRM1 (0.49) | SMN1; SMN2GAA | |
| SCHEMBL24894038 | 0.65 | SMN1; SMN2 (0.41) | SMN1; SMN2GAA | |
| SCHEMBL5000976 | 0.63 | SMN1; SMN2 (0.46) | SMN1; SMN2 | |
| SCHEMBL30396025 | 0.63 | SMN1; SMN2 (0.46) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190262371-A1 | METHODS AND COMPOSITION FOR THE TREATMENT OF RNA VIRAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190262371-A1 | METHODS AND COMPOSITION FOR THE TREATMENT OF RNA VIRAL INFECTIONS | POLRMT, EIF2AK2, NSUN3 | SMN1; SMN2 959/4885GAA 435/4885CBX7 1731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.